Publications dans lesquelles il/elle collabore avec Francisco Javier Narváez García (20)

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

2021

  1. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  2. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  3. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

  4. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

2020

  1. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 72, Núm. 2, pp. 216-224

  2. Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sjögren syndrome

    Rheumatology International, Vol. 40, Núm. 8, pp. 1259-1265

2018

  1. Primary respiratory disease in patients with systemic lupus erythematosus: Data from the Spanish rheumatology society lupus registry (RELESSER) cohort

    Arthritis Research and Therapy, Vol. 20, Núm. 1

  2. Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence

    Rheumatology International, Vol. 38, Núm. 12, pp. 2289-2296

2017

  1. Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study

    Arthritis Care and Research, Vol. 69, Núm. 1, pp. 38-45

  2. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus

    Seminars in Arthritis and Rheumatism, Vol. 47, Núm. 1, pp. 38-45

2016

  1. Characterization of patients with lupus nephritis included in a large cohort from the Spanish society of rheumatology registry of patients with systemic lupus erythematosus (RELESSER)

    Medicine (United States), Vol. 95, Núm. 9

  2. Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, pp. 40-47

  3. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry

    Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250

2015

  1. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus

    Lupus, Vol. 24, Núm. 7, pp. 720-729

  2. Cardiovascular events in systemic lupus erythematosus: A Nationwide Study in Spain from the RELESSER Registry

    Medicine (United States), Vol. 94, Núm. 29

  3. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the spanish rheumatology society lupus registry (RELESSER) with emphasis on complete versus incomplete lupus differences

    Medicine (United States), Vol. 94, Núm. 1, pp. e267

  4. Efficacy of anakinra in refractory adult-onset still's disease multicenter study of 41 patients and literature review

    Medicine (United States), Vol. 94, Núm. 39, pp. e1554

  5. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 717-723

2014

  1. Tocilizumab in refractory aortitis: A study on 16 patients and literature review

    Clinical and Experimental Rheumatology, Vol. 32, Núm. SUPPL.82